医药行业周报：吉利德Seladelpar获欧盟批准，用于治疗PBC

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [6]. Core Insights - Gilead's Seladelpar has received conditional approval from the European Commission for the treatment of primary biliary cholangitis (PBC) in patients who do not respond adequately to ursodeoxycholic acid (UDCA) [2]. - The pharmaceutical sector experienced a decline of 0.90% on February 24, 2025, underperforming the CSI 300 index by 0.68 percentage points, ranking 30th among 31 sub-industries [1]. - Notable stock performances included Koyuan Pharmaceutical (+19.99%), Shanghai Yizhong (+13.54%), and Jiankai Technology (+13.33%) on the gainers' list, while Anbiping (-8.95%), Meinian Health (-7.03%), and WuXi AppTec (-7.02%) led the decliners [1]. Summary by Sections Market Performance - The pharmaceutical sector's performance on February 24, 2025, was -0.90%, with medical equipment, blood products, and pharmaceutical distribution showing relatively better performance compared to medical research outsourcing, hospitals, and vaccines [1]. Company News - Huatai Medical reported a revenue of 2.066 billion yuan for 2024, a year-on-year increase of 25.18%, with a net profit of 673 million yuan, up 26.14% [2]. - Saifen Technology achieved a revenue of 315 million yuan in 2024, reflecting a growth of 28.65%, with a net profit of 85 million yuan, up 62.25% [3]. - Microelectrophysiology reported a revenue of 413 million yuan, a 25.51% increase, and a net profit of 52 million yuan, a significant rise of 817.40% [3]. - Haoyuan Pharmaceutical announced a stock incentive plan for 168 employees, granting 3 million restricted shares, representing 1.42% of total equity [3]. - CanSino received approval for a clinical trial of a combined vaccine for meningococcal disease [3].